Class summary at a glance.

Every drug in the Dipeptidyl Peptidase 4 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $6.52Bcombined across class
Total Rx claims: 8.1M2.0M unique beneficiaries
Generic mfrs (active): 15across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Sitagliptin

Brand: JANUVIA · 6.0M Part D claims (CY24) · 1.5M beneficiaries · First FDA approval: 2006-10-16

3 generic mfrs 3 plans require PA

Low NADAC$10.04

→

Avg plan cost$10.44

Part D spend $4.88B 1× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Linagliptin

Brand: Tradjenta · 2.1M Part D claims (CY24) · 486K beneficiaries · First FDA approval: 2011-05-09

7 generic mfrs 1 plans require PA

Low NADAC$16.80

→

Avg plan cost$16.80

Part D spend $1.64B 1× spread, current vs floor

Class share

25%

of class CY24 spend

View profile →

Linagliptin and Metformin

Brand: Jentadueto · — Part D claims (CY24) · First FDA approval: 2012-02-13

4 generic mfrs 4 plans require PA

Low NADAC$8.44

→

Avg plan cost$10.15

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Sitagliptin Hydrochloride Oral

Brand: BRYNOVIN · — Part D claims (CY24) · First FDA approval: 2025-04-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Sitagliptin and Metformin

Brand: JANUMET · — Part D claims (CY24) · First FDA approval: 2007-03-30

1 generic mfrs 5 plans require PA

Low NADAC$5.03

→

Avg plan cost$6.33

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.